239 related articles for article (PubMed ID: 16917205)
1. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
Kvols LK; Woltering EA
Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of new potential therapeutic applications of somatostatin analogs.
Pawlikowski M; Melen-Mucha G
Neuro Endocrinol Lett; 2003; 24(1-2):21-7. PubMed ID: 12743527
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
Hasskarl J; Kaufmann M; Schmid HA
Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs for diagnosis and treatment of cancer.
Weckbecker G; Raulf F; Stolz B; Bruns C
Pharmacol Ther; 1993 Nov; 60(2):245-64. PubMed ID: 7912834
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of somatostatin.
Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
[TBL] [Abstract][Full Text] [Related]
10. Advances in chemotherapy and biotherapy of endocrine tumors.
Oberg K
Curr Opin Oncol; 1998 Jan; 10(1):58-65. PubMed ID: 9466486
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
12. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
[TBL] [Abstract][Full Text] [Related]
13. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin, cortistatin and their receptors in tumours.
Volante M; Rosas R; Allìa E; Granata R; Baragli A; Muccioli G; Papotti M
Mol Cell Endocrinol; 2008 May; 286(1-2):219-29. PubMed ID: 18248880
[TBL] [Abstract][Full Text] [Related]
15. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
17. In situ radiotherapy with 111In-pentetreotide. State of the art and perspectives.
McCarthy KE; Woltering EA; Anthony LB
Q J Nucl Med; 2000 Mar; 44(1):88-95. PubMed ID: 10932605
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin analogs for cancer treatment and diagnosis: an overview.
Scarpignato C; Pelosini I
Chemotherapy; 2001; 47 Suppl 2():1-29. PubMed ID: 11275699
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
Ben-Shlomo A; Melmed S
IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogs in oncology: a look to the future.
Jenkins SA; Kynaston HG; Davies ND; Baxter JN; Nott DM
Chemotherapy; 2001; 47 Suppl 2():162-96. PubMed ID: 11275709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]